April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Extended Release Avastin Conjugated Gold Nanoparticles
Author Affiliations & Notes
  • R. Shukla
    Radiology & Ophthalmology,
    University of Missouri-Columbia, Columbia, Missouri
  • S. K. Nune
    Radiology,
    University of Missouri-Columbia, Columbia, Missouri
  • R. Kannan
    Radiology,
    University of Missouri-Columbia, Columbia, Missouri
  • K. V. Katti
    Radiology,
    University of Missouri-Columbia, Columbia, Missouri
  • D. P. Hainsworth
    Radiology,
    University of Missouri-Columbia, Columbia, Missouri
  • Footnotes
    Commercial Relationships  R. Shukla, None; S.K. Nune, None; R. Kannan, None; K.V. Katti, None; D.P. Hainsworth, None.
  • Footnotes
    Support  We wish to thank National Institutes of Health (Grant # 5R01CA119412), Research to prevent blindness and NAPE for generous funding for this project
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 2426. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. Shukla, S. K. Nune, R. Kannan, K. V. Katti, D. P. Hainsworth; Extended Release Avastin Conjugated Gold Nanoparticles. Invest. Ophthalmol. Vis. Sci. 2009;50(13):2426.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Avastin is widely used as a treatment for choroidal neovascularization, however, requires frequent intravitreal injections. Gold nano-particles (AuNP) are biocompatible, have affinity for neovascularization and can be bound to proteins to provide extended release drug delivery in the eye. We determined the distribution and delivery profile of Avastin conjugated gold nano-particles (Av/AuNP) in the rat eye.

Methods: : Av/AuNP were synthesized by one pot synthesis and characterized using standard physicochemical techniques. Their intraocular distribution was determined by angiography, neutron activation analysis and immunohistochemistry in the rat model. The duration of Avastin observed in rat eyes injected with Avastin alone or with Av/AuNP was compared.

Results: : Av/AuNP exhibit a characteristic SPR peak at around 535 nm. Size distribution analysis suggests the mean particle diameter 10-12 nm and they are stable in biological solutions. Av/AuNP are preferentially localized in the retinal region. Intraocular injection of Av/AuNP delivers Avastin longer than Avastin injection without AuNP.

Conclusions: : Av/AuNP functions as an extended release device for intraocular delivery of Avastin. This technology shows promise for treatment of patients with intraocular neovascularization without the need for frequent injections.

Keywords: age-related macular degeneration • retina • choroid: neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×